News and applications for life science research professionals
Subscribe to Bioscience Technology All
View Sample

FREE Email Newsletter Bioscience Technology Daily

HAT Activity Assay Kit

June 22, 2004 9:57 am | Articles | Comments

Histone acetyltransferases (HATs) play a crucial role in a variety of cellular functions such as gene transcription, differentiation, and proliferation. This HAT assay kit utilizes active recombinant HAT protein as a positive control and acetyl-CoA as a cofactor.


Membrane Protein

June 22, 2004 9:57 am | Articles | Comments

Epidermal Growth Factor receptor (EGFr) 170 kDa membrane protein is expressed in many normal epithelial tissues, particularly in the basal layers of stratified or pseudostratified and squamous epitheliums.


Bead-Based Assay Kits

June 22, 2004 9:57 am | Articles | Comments

LiquiChip™ bead-based xMAP™ assay kits facilitate research in drug discovery, cell signaling, oncogenesis, apoptosis, and immune disorders. Optimized immobilized substrates enable detection of a wide range of Tyr and Ser/Thr kinase activities without the need for radioactivity.


Human Growth Hormone ELISA

June 22, 2004 9:57 am | Articles | Comments

Bioactive hGH ELISA, for the measurement of biologically active human growth hormone, detects monomeric GH isoforms that possess both receptor binding sites, and thus is capable of receptor dimerization.

HSP27 (Heat Shock Protein) ELISA (3323)

June 22, 2004 9:56 am | Articles | Comments

HSP27 [pS82] phosphoELISA™ is sensitive to 1,000 cells/well, demonstrated with HeLa cell lysates. Additional validated cell lines include THP-1, HT1080, Jurkat and 293 cells.

HDAC8 Activity Assay (3321)

June 22, 2004 9:56 am | Articles | Comments

HDAC8 Colorimetric/Fluorometric Activity Assay/Drug Discovery Kit is HTS-friendly assay and allows real-time monitoring of HDAC activity. This is made possible by HDAC-TRAC™ substrate and buffer, which also enables a choice of either colorimetric or fluorometric detection.

Bayer Adopts Tripos Informatics Technology to Streamline Drug Discovery 06/21/04

June 21, 2004 10:53 am | Articles | Comments

By Catherine Shaffer The preclinical phase of drug development is a large portion of the total expense of research and development, with much of this effort focused on generating new chemical compounds and screening them for activity against disease targets. Bayer Healthcare, Leverkusen, Germany, has adopted a new informatics software system to help manage these millions of compounds.


Statistical Megastudy Turns Up Genetic Surprise for Pravastatin Patients 6/16/04

June 16, 2004 12:32 pm | Articles | Comments

By Catherine Shaffer A new pharmacogenetic study of cholesterol-lowering statin drugs could lead to better treatment for millions of patients. A collaboration among Harvard Medical School, Brigham and Women's Hospital, both in Boston, and the defunct Variagenics Inc., formerly of Cambridge, Mass., published in the June 16 issue of the Journal of the American Medical Association (JAMA)


Telltale Heart: Celera Diagnostics Finds Markers of Myocardial Infarction Risk 6/15/04

June 15, 2004 11:27 am | Articles | Comments

By Don Monroe Celera Diagnostics (CD), Alameda, Calif., disclosed two more genetic markers that it says are associated with heart-attack risk in caucasians. Although the work is still in an early stage, this type of marker "could be useful in identifying people who should be on statins, or other cholesterol-lowering agents, who otherwise might not be candidates," says Thomas White, chief scientific officer at the company.


Delivery System for RNAi Gene Therapy Opens Door to the Brain 6/14/04

June 14, 2004 12:02 pm | Articles | Comments

By Catherine Shaffer The use of gene therapy in the treatment of brain cancer is hindered by drug delivery problems. Large molecules such as monoclonal antibodies and viral vectors cannot cross the blood-brain barrier. A featured article in the June 1 issue of Clinical Cancer Research now describes the successful delivery of a nonviral RNAi gene therapy to brain tumors in mice, resulting in a significant increase in survival times.


Novel Protein Kinases May Lead to Drug Targets for Alzheimer’s Disease 6/11/04

June 11, 2004 9:40 am | Articles | Comments

By Mark Terry Researchers with Proteome Sciences Plc., Cobham, UK, recently identified 12 additional phosphorylation sites on the tau protein. Twenty-five phosphorylation sites had previously been identified on tau, which has been implicated in Alzheimer's disease (AD). Neurofibrillary tangles develop from a hyperphosphorylated form of the tau protein, and these are hypothesized to be the cause of neuronal cell death. By using a proprietary mass spectrometry technology, the ProteoShop toolbox, they were able to analyze and identify specific kinases that have the potential to be drug targets for AD. Results of their study were presented May 27 at the American Society for Mass Spectrometry Meeting in Nashville, Tenn.


Vertex Continues Collaboration to Combat CF 06/10/04

June 10, 2004 12:14 pm | Articles | Comments

By Don Monroe Vertex Pharmaceuticals Inc., Cambridge, Mass., will get roughly $21 million through 2005 to continue its late-stage drug discovery collaboration with Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the company announced on May 24.


Is There a Genetic Basis for Who Experiences Drug Side Effects? 6/09/04

June 9, 2004 11:38 am | Articles | Comments

By Don Monroe First Genetic Trust Inc. (FGT), Deerfield, Ill., and GlaxoSmithKline, Brentford, UK, will again collaborate on a study of possible genetic markers associated with adverse drug reactions, FGT announced on May 25.


NIMH Makes Brain Gene Studies Go Head to Head 6/07/04

June 8, 2004 11:45 am | Articles | Comments

By Aaron Sender Researchers at the National Institute of Mental Health's Clinical Brain Disease Branch (NIMH-CBDB) have begun pitting several microarray platforms against each other, trying to find the ones


Reporter Vectors

June 8, 2004 9:49 am | Articles | Comments

Promega Rapid Response™ Reporter Vectors reduce the risk of secondary effects and allow measurement of smaller and more transient changes in transcription compared to their predecessors.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.